Royce & Associates reports 5.95% stake in Apyx
Royce & Associates LP has filed an amended Schedule 13G reporting beneficial ownership of Apyx Medical Corporation common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royce & Associates LP has filed an amended Schedule 13G reporting beneficial ownership of Apyx Medical Corporation common stock. The firm reports beneficial ownership of 2,443,035 shares, representing 5.95% of the outstanding common stock, as of the event date of 12/31/2025. Royce & Associates has sole power to vote and dispose of all of these shares and no shared voting or dispositive power.
The filing explains that the securities are held in one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce & Associates states that the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Apyx Medical. The firm also disclaims any pecuniary interest and does not consider itself part of a group with Franklin Resources, its affiliates, or their principal shareholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Royce & Associates LP report in APYX common stock?
Is Royce & Associates LP seeking to influence control of Apyx Medical (APYX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.